Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.
Last updated: 2026-11-18 05:09:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Jade Biosciences, Inc. (JBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.44, with a market capitalization of $1.03B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.98 to $28.00. This page covers its latest market performance, valuation, price trends and company information.
$1.03B | |
$15.27 | |
$16.23 | |
$14.64 | |
$15.34 | |
1.91M | |
898.42K | |
-- | |
$28.00 | |
$10.98 | |
-- | |
-- |
Jade Biosciences, Inc. (JBIO) last closed at $15.44 as of 2026-11-17 23:14:00, up 0.68% ($0.10) from the previous close of $15.34.
During the latest regular trading session, JBIO traded between $14.64 and $16.23, with a volume of 1.91M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Jade Biosciences, Inc. (JBIO) moved from $15.07 to $15.44, representing a gain of 2.46% ($0.37).
The stock traded between $13.65 and $17.16 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 787.86 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 26.2%
JBIO is currently trading at $15.44, placing it 26.2% of the way from its 52-week low of $10.98 to its 52-week high of $28.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Jade Biosciences, Inc. and JBIO stock.
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.71) by 40.85 percent. This is a 12.5 percent increase over losses of $(0.48) per share from
Eligible investors can buy real shares of Jade Biosciences, Inc. (JBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to JBIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between JBIO shares and USD.
JBIO Shares to USD
1.00 JBIO shares = 15.44 USD
Calculations are estimates based on the latest available price and are for reference only.